GMAB logo

Genmab A/S (GMAB)

$25.61

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on GMAB

Market cap

$16.45B

EPS

0.24

P/E ratio

136.2

Price to sales

37.33

Dividend yield

--

Beta

0.853899

Price on GMAB

Previous close

$25.27

Today's open

$25.05

Day's range

$24.88 - $25.66

52 week range

$20.23 - $35.43

Profile about GMAB

CEO

JanG.J. van de Winkel

Employees

3029

Headquarters

Valby,

Exchange

Nasdaq Global Select

Shares outstanding

642384080

Issue type

American Depository Receipt

GMAB industries and sectors

Healthcare

Biotechnology & Life Sciences

News on GMAB

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others.

news source

GlobeNewsWire • Jun 16, 2026

news preview

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of June 12, 2026, Orbis Investment Management Limited controlled the voting rights to 3,112,476 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S.   The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement.

news source

GlobeNewsWire • Jun 15, 2026

news preview

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL) who may have limited treatment options due to advanced age or multiple health conditions. Results from the Phase 2 EPCORE® DLBCL-3 study showed an overall response rate (ORR) of 67% and a complete response (CR) rate of 58% wi.

news source

Business Wire • Jun 13, 2026

news preview

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 15,894 restricted stock units and 15,494 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.

news source

GlobeNewsWire • Jun 11, 2026

news preview

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from a post-hoc subgroup analysis from the pivotal Phase 3 EPCORE® FL-1 trial, evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, in combination with rituximab and lenalidomide (epcoritamab + R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), which showed that epcoritamab + R2 delivered consistent and sustained efficacy benefits across clinically relev.

news source

Business Wire • Jun 11, 2026

news preview

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

news source

GlobeNewsWire • May 29, 2026

news preview

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

Media Release COPENHAGEN, Denmark; May 21, 2026 Twenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral presentations Three abstracts will show the ongoing clinical trial evaluations of the safety and efficacy of Genmab's investigational late-stage medicines, rinatabart sesutecan and petosemtamab Data evaluating epcoritamab will demonstrate outcomes across monotherapy, combination regimens and fixed-duration use, including outpatient administration and use in earlier lines of treatment Genmab A/S (Nasdaq: GMAB ) announced today that 23 abstracts, including 20 abstracts evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, will be presented or published at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, from May 29-June 2, and at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden, from June 11-14. Key presentations at ASCO and EHA will highlight data evaluating the potential utility of epcoritamab across multiple settings, including as a monotherapy, in combination regimens, in fixed-duration use and in earlier lines of therapy.

news source

GlobeNewsWire • May 21, 2026

news preview

Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript

Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript

news source

Seeking Alpha • May 14, 2026

news preview

Genmab Announces Financial Results for the First Quarter of 2026

May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased 25% compared to the first three months of 2025 , to $896 million FDA approved an sBLA to remove the recommendation for 24-hour hospitalization for patients with third line plus relapsed/refractory DLBCL Remained focused on disciplined investment in our late-stage portfolio, EPKINLY ® (epcoritamab), Rina-S ® , and petosemtamab, including launch readiness “We made tangible progress in the first quarter as we continue to integrate Merus™ and advance our late-stage portfolio - EPKINLY, Rina-S and petosemtamab. Across the business, our focus remained on disciplined execution, progressing these programs toward key readouts and preparing for potential launches to have an impact on more patients,” said Jan van de Winkel, Ph.D.

news source

GlobeNewsWire • May 7, 2026

news preview

Genmab A/S Share Capital Reduction

Company Announcement COPENHAGEN, Denmark; April 17, 2026 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 19, 2026, it was decided to reduce the Company's share capital with nominally DKK 1,900,000 by cancellation of 1,900,000 of the Company's holding of shares with a nominal value of DKK 1 each. The share capital reduction has today been registered with the Danish Business Authority.

news source

GlobeNewsWire • Apr 17, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Genmab A/S

Open an M1 investment account to buy and sell Genmab A/S commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in GMAB on M1